<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605185</url>
  </required_header>
  <id_info>
    <org_study_id>JS001D-C-103</org_study_id>
    <nct_id>NCT04605185</nct_id>
  </id_info>
  <brief_title>Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Dose Escalation Study Of Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the single-center, open-label phase I clinical trial to evaluate tolerability,&#xD;
      safety and efficacy of Donafenib and JS001 in combination with TCAE in patients with&#xD;
      Unresectable Hepatocellular Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase I clinical trial is to determine the maximum tolerated dose (MTD) and dose limiting&#xD;
      toxicity (DLT) of Donafenib in this regimen, and select an acceptable safe dose for the phase&#xD;
      II clinical trial(RP2D).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity(DLT)</measure>
    <time_frame>21 days after the first dose of JS001 and Donafenib, assessed up to 2 years</time_frame>
    <description>Dose limiting toxicity (DLT) is referred to grade 3 non-hematological toxicity or grade 4 hematological toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the date of randomization until death due to any cause, assessed up to 2 years.</time_frame>
    <description>The Kaplan-Meier survival from the initiation date of first cycle until death from any cause or the last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of objective disease progression or death, assessed up to 2 years.</time_frame>
    <description>The Kaplan-Meier survival from the initiation date of first cycle until the date of first documented progression or date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From the date of first documented response (RECIST 1.1.) until the first date of documented progression or death in the absence of disease progression, assessed up to 2 years.</time_frame>
    <description>defined as the time between the first assessment of a tumor as PR or CR and the first assessment as PD or any cause of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Donafenib/JS001/TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donafenib and JS001 Combined With TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib Tosilate Tablets</intervention_name>
    <description>100mg Qd/150mg Qd/100mg Bid, po</description>
    <arm_group_label>Donafenib/JS001/TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toripalimab Injection</intervention_name>
    <description>240 mg, iv drip,q3w</description>
    <arm_group_label>Donafenib/JS001/TACE</arm_group_label>
    <other_name>JS001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 (inclusive), male or female;&#xD;
&#xD;
          -  Diagnosis of Unresectable Hepatocellular Carcinoma confirmed clinically or&#xD;
             histologically or cytologically according to the &quot;Guidelines for diagnosis and&#xD;
             treatment of primary liver cancer&quot; (2019 Edition);&#xD;
&#xD;
          -  At least one measurable lesion (according to RECIST v1.1)&#xD;
&#xD;
          -  ECOG performance status score of 0 -1;&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          -  Fully understand this research and voluntarily sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diffuse liver cancer；&#xD;
&#xD;
          -  Refractory hepatic encephalopathy, refractory ascites, or hepatorenal syndrome；&#xD;
&#xD;
          -  Pregnancy or lactation；&#xD;
&#xD;
          -  Patients with extrahepatic diffusion；&#xD;
&#xD;
          -  Spontaneous tumor rupture；&#xD;
&#xD;
          -  Expected non-compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanzhi Gu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanzhi Gu, MD</last_name>
    <phone>+86-0731-89762041</phone>
    <email>105575191@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanzhi Gu, MD</last_name>
      <phone>+8673189762041</phone>
      <email>105575191@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

